NCT03312400View on ClinicalTrials.gov

Low-Dose Danazol for the Treatment of Telomere Related Diseases

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 8, 2018

Primary Completion Date

April 29, 2026

Study Completion Date

October 29, 2027

Conditions
Telomere Disease
Interventions
DRUG

Danazol

Adult: 200 mg daily versus 400 mg daily Pediatric: 4 mg/kg/day divided in twice daily dose (max 400 mg daily) for 6 months or 2 mg/kg/day divided in twice daily dose (max 200 mg daily) for 6 months.

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH